Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA Update: Romosozumab’s Uncertain Future; Plus Tocilizumab Approved for GCA

  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Hirschler B. Heart safety clouds hopes for Amgen, UCB bone drug. Reuters. 2017 May 23.
  2. Amgen Inc. News release: Amgen and UCB announce top-line phase 3 data from active-comparator study of Evenity (romosozumab) in postmenopausal women with osteoporosis. 2017 May 21.
  3. Roche. News release: FDA grants priority review for Roche’s Actemra/RoActemra (tocilizumab) supplemental biologics license application for giant cell arteritis, a form of vasculitis. 2017 Jan 24.
  4. Genentech Inc. News release: FDA approves Genentech’s Actemra (tocilizumab) for giant cell arteritis. 2017 May 22.

Related Articles

    Updates on Giant Cell Arteritis

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

    Case Report: Giant Cell Arteritis-Related Stroke

    Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…